Nathan Hanan
GlaxoSmithKline (United States)(US)Simulation Technologies (United States)(US)Smiths Detection (Canada)(CA)GlaxoSmithKline (Brazil)(BR)Kalamazoo College(US)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Statistical Methods in Clinical Trials, Parkinson's Disease Mechanisms and Treatments, Antifungal resistance and susceptibility
Most-Cited Works
- → Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk(2018)177 cited
- → Modeling Nikkomycin Z Dosing and Pharmacology in Murine Pulmonary Coccidioidomycosis Preparatory to Phase 2 Clinical Trials(2014)62 cited
- → Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus(2022)32 cited
- → A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation(2021)18 cited
- → Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective(2023)8 cited
- → The Critical Path for Alzheimer’s Disease (CPAD) Consortium: A platform for pre‐competitive data sharing, standardization, and analysis to support quantitative tools for AD drug development(2021)7 cited